Citation Impact
Citing Papers
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer
2009
Pilot Clinical Trial of Hedgehog Pathway Inhibitor GDC-0449 (Vismodegib) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma
2014
Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR -Mutant Lung Cancers
2013 Standout
First-Line Gefitinib for Patients With Advanced Non–Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Without Indication for Chemotherapy
2009
Evolution of the Cancer Stem Cell Model
2014 Standout
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Gastric cancer
2016 Standout
Smarter drugs emerging in pancreatic cancer therapy
2014
The molecular hallmarks of epigenetic control
2016 Standout
Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)
2017
Survival and disease-progression benefits with treatment regimens for advanced colorectal cancer: a meta-analysis
2007
Lung cancer epigenetics: From knowledge to applications
2017
Targeted therapies in breast cancer: are heart and vessels also being targeted?
2012
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
2010
Breast cancer
2016 Standout
A Novel Indication for Panobinostat as a Senolytic Drug in NSCLC and HNSCC
2017
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
2014 Standout
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016 Standout
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial
2010 Standout
Lung Cancer
2008 Standout
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment
2016 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
2014 Standout
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
2015
Lung cancer: New biological insights and recent therapeutic advances
2011
Chemotherapy for advanced gastric cancer
2010
Cancer stem cells revisited
2017 Standout
Chemotherapy for advanced gastric cancer
2005
Checking consistency in mixed treatment comparison meta‐analysis
2010 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Pancreatic Adenocarcinoma
2014 Standout
Cellular senescence in ageing: from mechanisms to therapeutic opportunities
2020 Standout
Cancer-associated cachexia
2018 Standout
A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer
2012
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Pyroptosis: mechanisms and diseases
2021 Standout
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Targeting apoptosis in cancer therapy
2020 Standout
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Promises and challenges for the implementation of computational medical imaging (radiomics) in oncology
2017 Standout
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study)
2010
Adjuvant Therapy for Colon Cancer 2005: New Options in the Twenty-First Century
2006
Remodelling the extracellular matrix in development and disease
2014 Standout
Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment
2011
Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition
2013
Cancer treatment and survivorship statistics, 2012
2012 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment
2013
Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer
2007 Standout
Oxidative Stress in Cancer
2020 Standout
Epigenetic modifications as therapeutic targets
2010
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Targeting autophagy in cancer
2017 Standout
Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung
2011
Treatment of Acute Lymphoblastic Leukaemia
2007
Epigenetic modifications and human disease
2010 Standout
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
2008 Standout
A decade of exploring the cancer epigenome — biological and translational implications
2011 Standout
Epigenetic Determinants of Cancer
2016
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
The future of epigenetic therapy in solid tumours—lessons from the past
2013
Histone Deacetylase Inhibitors as Anticancer Drugs
2017
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
2006
Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer
2008
Chemotherapy for advanced gastric cancer
2017 Standout
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline
2017
Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
2015
NCCN Task Force Report: Management of Neuropathy in Cancer
2009
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
2014 Standout
Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases
2010
Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial
2012
Combination therapy in combating cancer
2017 Standout
Randomized Phase III Trial of Single-Agent Pemetrexed Versus Carboplatin and Pemetrexed in Patients With Advanced Non–Small-Cell Lung Cancer and Eastern Cooperative Oncology Group Performance Status of 2
2013
NCCN Task Force Report: Bone Health in Cancer Care
2013
Liquid Biopsies: Genotyping Circulating Tumor DNA
2014 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
2015 Standout
Iron and Cancer
2018
American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update
2014 Standout
Stromal response to Hedgehog signaling restrains pancreatic cancer progression
2014
Works of Sachdev Thomas being referenced
Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients With Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2
2008
A phase II trial of Triapine® (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503
2009
A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321
2014
Mortality associated with daily bolus 5‐fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin
2004
Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
2009
A phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): Interim analysis of a University of Chicago phase II consortium study.
2012
Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (Alliance)
2015
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Risedronate for the Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer
2008
Final analysis of a phase IB/randomized phase II study of gemcitabine (G) plus placebo (P) or vismodegib (V), a hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago phase II consortium study.
2013
Final Results of a Phase II Trial Evaluating Trastuzumab and Bevacizumab as First Line Treatment of HER2-Amplified Advanced Breast Cancer.
2009
Randomized Phase II Trial of Three Schedules of Pemetrexed and Gemcitabine As Front-Line Therapy for Advanced Non–Small-Cell Lung Cancer
2005